Single-Drug Approach with Edoxaban is Effective for Resolving Non-Acute Cancer-Associated Venous Thrombosis: A Single-Arm Retrospective Analysis

• Main Authors: Hirokazu Toshima, Atsushi Hisamatsu, Kouji Kobayashi, Hiroo Ishida, Ken Shimada
• Format: Article
• Language: English
• Published: MDPI AG 2020-06-01
• Series: Cancers
• Subjects: edoxaban; DOAC; single-drug approach; cancer-associated venous thrombosis; deep-vein thrombosis; pulmonary embolism
• Online Access: https://www.mdpi.com/2072-6694/12/7/1711

Recently, cancer-related venous thromboembolism (VTE) has been termed “cancer-associated thrombosis (CAT)” and is the focus of current research. We retrospectively investigated the efficacy of a single-drug approach with edoxaban for the treatment of non-acute CAT. Thirty-two non-acute CAT patients who received edoxaban were analyzed. The primary endpoint of this analysis was the thrombus disappearance rate at the first evaluation. Secondary endpoints included progression/recurrence of VTE, major bleeding, and D-dimer levels. The thrombus disappearance rate was 62.5%. Therefore, the null hypothesis for the primary endpoint (thrombus disappearance rate of ≤32.0%) was rejected (<i>p</i> = 0.00038) based on the rate of the previous study as the historical control. Recurrent VTE and major bleeding occurred in two patients each. After the start of treatment with edoxaban, a significant difference in D-dimer levels was observed (<i>p</i> = 0.00655). We demonstrated that a single-drug approach with edoxaban is a potential treatment option for non-acute CAT.